English | 简体中文 | 繁體中文 | 한국어
  Home | Services | Partners | Events | About us | Contact us | Login
Thursday, May 23, 2013  
Share:
Jamie Macdonald Assumes CEO Role at INC Research; Succession Plan Complete

Raleigh, N.C., Jan. 7, 2013 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today reported the completion of its CEO succession plan announced in August 2012.  

Effective Jan. 1, 2013, Jamie Macdonald, formerly Chief Operating Officer for the Company, officially assumed the role of INC Research's new Chief Executive Officer. Mr. Macdonald replaced James T. Ogle, who remains with the Company as Chairman of the Board.  Alistair Macdonald, previously President, Clinical Development Services, assumed the role of Chief Operating Officer.

"With the completion of these changes and the additional executive appointments made in recent months, INC Research is strategically positioned for continued growth," said James Ogle, Chairman of the Board. "We greatly appreciate Jamie and Alistair's contributions to date and look forward to their future leadership as we continue to advance INC Research as a leading provider of clinical development solutions globally."

"I am excited about 2013 and the opportunities it holds for INC Research and our customers," noted Jamie Macdonald, Chief Executive Officer for the Company. "We will continue to leverage our enhanced global scale, renowned therapeutic capability and enhanced Trusted Process® to offer increasingly innovative clinical development solutions that improve efficiency and ultimately lead our customers to make better decisions faster. The future for our industry and our Company has never been brighter and we look forward to continuing to partner with our customers in the delivery of new medicines to market to improve world health."

About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1 (513) 345-1685





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

HUG#1668763
Copyright © Thomson Reuters 2013. All rights reserved.
European Press Release
Canaccord Genuity Initiates Coverage on Copper Mountain (TSX:CUM) with Buy Rating - Video Posted on InvestmentPitch.com  
May 23, 2013 00:00 ET
Endurance Announces Peter Mills to Head Specialty Reinsurance  
May 22, 2013 22:15 ET
Aker Solutions to double subsea manufacturing capacity in Brazil  
May 22, 2013 21:45 ET
Europa Casino Debuts All-New Website to Tremendous Fanfare  
May 22, 2013 19:10 ET
STMicroelectronics Announces Jean-Marc Chery as General Manager of the Embedded Processing Solutions Segment and New Appointments to the Corporate Strategic Committee  
May 22, 2013 17:01 ET
More News >>
Copyright © 2013 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 866 599 7292 | Hong Kong: +852 3101 7299 | Singapore: +65 6321 9104 | Seoul: +82 2 737 3600 | Tokyo: +81 3 5791 1818